Abstract
The etiology of prostate cancer, the second most common cancer in men globally, has a strong heritable component. While rare coding germline variants in several genes have been identified as risk factors from candidate gene and linkage studies, the exome-wide spectrum of causal rare variants remains to be fully explored. To more comprehensively address their contribution, we analysed data from 37,184 prostate cancer cases and 331,329 male controls from five cohorts with germline exome/genome sequencing and one cohort with imputed array data from a population enriched in low-frequency deleterious variants. Our gene-level collapsing analysis revealed that rare damaging variants in SAMHD1 as well as genes in the DNA damage response pathway (BRCA2, ATM and CHEK2) are associated with the risk of overall prostate cancer. We also found that rare damaging variants in AOX1 and BRCA2 were associated with increased severity of prostate cancer in a case-only analysis of aggressive versus non-aggressive prostate cancer. At the single-variant level, we found rare non-synonymous variants in three genes (HOXB13, CHEK2, BIK) significantly associated with increased risk of overall prostate cancer and in four genes (ANO7, SPDL1, AR, TERT) with decreased risk. Altogether, this study provides deeper insights into the genetic architecture and biological basis of prostate cancer risk and severity.
Competing Interest Statement
J.M., N.C., O.B., R.D., A.N., A.O., A.A., Q.W., L.A.-D., R.M., B.D., K.C., S.P., M.A.F. are current employees and/or stockholders of AstraZeneca. A.W.Z receives grant funding and consulting fees from AstraZeneca. L.A.M. is on the advisory board and holds equity interest in Convergent Therapeutics. A.M. is a former employee of AstraZeneca and current employee of GSK and a stockholder of AstraZeneca and GSK. C.H. was an employee and stockholder of AZ at the time of study. P.W.K. is a co-founder and employee of Convergent Therapeutics.
Funding Statement
The generation of the UKB data was funded by the UKB Exome Sequencing Consortium (UKB-ESC) members: AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer, Regeneron, and Takeda. The MCPS has received funding from the Mexican Health Ministry, the National Council of Science and Technology for Mexico, the Wellcome Trust (058299/Z/99), Cancer Research UK, British Heart Foundation, and the UK Medical Research Council (MC_UU_00017/2). M.P. received funding from Prostate Cancer Foundation Challenge Award 18CHAL05, NIH/NCI P01 CA228696, and Rebecca and Nathan Milikowsky funded. L.A.M., P.K., K.S., M.P., K.O., and V.J. received funding from the National Cancer Institute (P01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study has approval from the North-West Multi-centre Research Ethics Committee (11/NW/0382), and participants provided informed consent. The The Mexico City Prospective Study was approved by the Mexican National Council for Science and Technology, the Mexican Ministry of Health and the University of Oxford ethics committees. The 100,000 Genomes Project study was approved by the National Research Ethics Committee. The FinnGen study approval was obtained by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (number HUS/990/2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-first authors
Data Availability
Summary statistics for the genetic associaiton testing are provided in Supplementary Tables. UK Biobank data may be requested via application to the UK Biobank.
